sur Mainz BioMed N.V.
Mainz Biomed Announces Presentation of eAArly DETECT Study Results at Digestive Disease Week 2024
Mainz Biomed N.V. will present its eAArly DETECT study findings at the upcoming Digestive Disease Week (DDW) in Washington, D.C. from May 18-21, 2024. The study, focusing on colorectal cancer and advanced adenoma screening, reports a 97% sensitivity and specificity for colorectal cancer detection and 82% sensitivity for advanced adenomas.
The eAArly DETECT study, conducted at 21 specialized gastroenterology sites across the U.S., employed a multimodal screening test combining Fecal Immunochemical Test (FIT) with DNA and mRNA biomarkers and an artificial intelligence algorithm. This approach aims to improve early detection rates for colorectal cancer and significant precancerous conditions, ultimately advancing cancer prevention strategies.
The findings will be extensively discussed in a session at DDW 2024 titled "NOVEL STOOL-BASED NON-INVASIVE EARLY DETECTION OF COLORECTAL CANCER AND PRECANCEROUS LESIONS BY CLASSIC FIT COMBINED WITH NUCLEIC ACID-BASED BIOMARKER SIGNATURES." Mainz Biomed's presentation is part of a broader effort to enhance colorectal cancer screening methods and reduce global cancer mortality rates.
R. E.Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés. Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Mainz BioMed N.V.